| 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus |
200 |
| EULAR recommendations for the use of imaging in large vessel vasculitis in clinical practice |
118 |
| EULAR recommendations for the management of antiphospholipid syndrome in adults |
109 |
| 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus |
98 |
| 2018 update of the EULAR recommendations for the management of Behcet's syndrome |
96 |
| 2018 EULAR recommendations for physical activity in people with inflammatory arthritis and osteoarthritis |
80 |
| Circular RNA VMA21 protects against intervertebral disc degeneration through targeting miR-200c and X linked inhibitor-of-apoptosis protein |
54 |
| Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate) |
51 |
| Efficacy and safety of tocilizumab in patients with refractory Takayasu arteritis: results from a randomised, double-blind, placebo-controlled, phase 3 trial in Japan (the TAKT study) |
51 |
| Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study |
51 |
| Immunological and clinical effects of low-dose interleukin-2 across 11 autoimmune diseases in a single, open clinical trial |
49 |
| Lack of placental transfer of certolizumab pegol during pregnancy: results from CRIB, a prospective, postmarketing, pharmacokinetic study |
47 |
| Clinical phenotypes of IgG4-related disease: an analysis of two international cross-sectional cohorts |
46 |
| Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study |
46 |
| Clinical relevance of HEp-2 indirect immunofluorescent patterns: the International Consensus on ANA patterns (ICAP) perspective |
44 |
| Global, regional and national burden of rheumatoid arthritis 1990-2017: a systematic analysis of the Global Burden of Disease study 2017 |
44 |
| Rheumatic disorders associated with immune checkpoint inhibitors in patients with cancer-clinical aspects and relationship with tumour response: a single-centre prospective cohort study |
43 |
| Classification criteria for autoinflammatory recurrent fevers |
43 |
| TNF blockers inhibit spinal radiographic progression in ankylosing spondylitis by reducing disease activity: results from the Swiss Clinical Quality Management cohort |
42 |
| Novel therapies for immune-mediated inflammatory diseases: What can we learn from their use in rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, psoriasis, Crohn's disease and ulcerative colitis? |
42 |
| Mycophenolate mofetil versus cyclophosphamide for remission induction in ANCA-associated vasculitis: a randomised, non-inferiority trial |
41 |
| Prevotella copri in individuals at risk for rheumatoid arthritis |
41 |
| Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2) |
39 |
| Treating juvenile idiopathic arthritis to target: recommendations of an international task force |
39 |
| Lupus nephritis is linked to disease-activity associated expansions and immunity to a gut commensal |
38 |
| EULAR recommendations for the health professional's approach to pain management in inflammatory arthritis and osteoarthritis |
38 |
| 2018 update of the EULAR recommendations for the management of hand osteoarthritis |
37 |
| Open-label, multicentre, dose-escalating phase II clinical trial on the safety and efficacy of tadekinig alfa (IL-18BP) in adult-onset Still's disease |
35 |
| Synovial cellular and molecular signatures stratify clinical response to csDMARD therapy and predict radiographic progression in early rheumatoid arthritis patients |
35 |
| Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force |
35 |
| Outcomes of patients with systemic sclerosis treated with rituximab in contemporary practice: a prospective cohort study |
35 |
| Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammation |
34 |
| Long-term efficacy of remission-maintenance regimens for ANCA-associated vasculitides |
33 |
| Serious infection across biologic-treated patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis |
33 |
| Reliability of a consensus-based ultrasound definition and scoring for enthesitis in spondyloarthritis and psoriatic arthritis: an OMERACT US initiative |
33 |
| Impact of risk factors associated with cardiovascular outcomes in patients with rheumatoid arthritis |
33 |
| Incidence rates of inflammatory bowel disease in patients with psoriasis, psoriatic arthritis and ankylosing spondylitis treated with secukinumab: a retrospective analysis of pooled data from 21 clinical trials |
33 |
| Short-term progression of interstitial lung disease in systemic sclerosis predicts long-term survival in two independent clinical trial cohorts |
33 |
| Assay variation in the detection of antinuclear antibodies in the sera of patients with established SLE |
31 |
| Metabolic and cardiovascular benefits of hydroxychloroquine in patients with rheumatoid arthritis: a systematic review and meta-analysis |
31 |
| Single-cell RNA-seq analysis reveals the progression of human osteoarthritis |
30 |
| CircSERPINE2 protects against osteoarthritis by targeting miR-1271 and ETS-related gene |
30 |
| Prophylactic effect of trimethoprim-sulfamethoxazole for pneumocystis pneumonia in patients with rheumatic diseases exposed to prolonged high-dose glucocorticoids |
30 |
| Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III randomised, double-blind, placebo-controlled trial (RAJ4) in Japan |
30 |
| Arthroscopic partial meniscectomy versus placebo surgery for a degenerative meniscus tear: a 2-year follow-up of the randomised controlled trial |
30 |
| Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to conventional DMARDs: a randomised, double-blind, placebo-controlled phase III trial (RAJ3) |
29 |
| Risk of serious infections in tocilizumab versus other biologic drugs in patients with rheumatoid arthritis: a multidatabase cohort study |
29 |
| Synovial macrophage M1 polarisation exacerbates experimental osteoarthritis partially through R-spondin-2 |
28 |
| Safety and effectiveness of upadacitinib or adalimumab plus methotrexate in patients with rheumatoid arthritis over 48 weeks with switch to alternate therapy in patients with insufficient response |
28 |
| Photosensitivity and type I IFN responses in cutaneous lupus are driven by epidermal-derived interferon kappa |
27 |
| Limited radiographic progression and sustained reductions in MRI inflammation in patients with axial spondyloarthritis: 4-year imaging outcomes from the RAPID-axSpA phase III randomised trial |
26 |
| Apoptosis-derived membrane vesicles drive the cGAS-STING pathway and enhance type I IFN production in systemic lupus erythematosus |
26 |
| Trimethoprim-sulfamethoxazole prophylaxis prevents severe/life-threatening infections following rituximab in antineutrophil cytoplasm antibody-associated vasculitis |
26 |
| A pivotal phase III, randomised, placebo-controlled study of belimumab in patients with systemic lupus erythematosus located in China, Japan and South Korea |
26 |
| Tocilizumab in patients with adult-onset still's disease refractory to glucocorticoid treatment: a randomised, double-blind, placebo-controlled phase III trial |
26 |
| MRI lesions in the sacroiliac joints of patients with spondyloarthritis: an update of definitions and validation by the ASAS MRI working group |
25 |
| Autoantibodies and scleroderma phenotype define subgroups at high-risk and low-risk for cancer |
25 |
| The EuroMyositis registry: an international collaborative tool to facilitate myositis research |
25 |
| Consensus-based recommendations for the use of biosimilars to treat rheumatological diseases |
25 |
| To switch or not to switch: results of a nationwide guideline of mandatory switching from originator to biosimilar etanercept. One-year treatment outcomes in 2061 patients with inflammatory arthritis from the DANBIO registry |
25 |
| Effects of B-cell directed therapy on the preclinical stage of rheumatoid arthritis: the PRAIRI study |
25 |
| Genetics of rheumatoid arthritis: 2018 status |
24 |
| Video clip assessment of a salivary gland ultrasound scoring system in Sjogren's syndrome using consensual definitions: an OMERACT ultrasound working group reliability exercise |
24 |
| REDD1/autophagy pathway promotes thromboinflammation and fibrosis in human systemic lupus erythematosus (SLE) through NETs decorated with tissue factor (TF) and interleukin-17A (IL-17A) |
24 |
| Treatment of primary Sjogren's syndrome with ianalumab (VAY736) targeting B cells by BAFF receptor blockade coupled with enhanced, antibody-dependent cellular cytotoxicity |
24 |
| Safety, immunogenicity and efficacy after switching from reference infliximab to biosimilar SB2 compared with continuing reference infliximab and SB2 in patients with rheumatoid arthritis: results of a randomised, double-blind, phase III transition study |
23 |
| Effect of pregnancy on disease flares in patients with systemic lupus erythematosus |
23 |
| Impact of Janus kinase inhibitors on risk of cardiovascular events in patients with rheumatoid arthritis: systematic review and meta-analysis of randomised controlled trials |
23 |
| Therapeutic interleukin-6 blockade reverses transforming growth factor-beta pathway activation in dermal fibroblasts: insights from the faSScinate clinical trial in systemic sclerosis |
23 |
| DNA methylation mapping identifies gene regulatory effects in patients with systemic lupus erythematosus |
22 |
| Progressive skin fibrosis is associated with a decline in lung function and worse survival in patients with diffuse cutaneous systemic sclerosis in the European Scleroderma Trials and Research (EUSTAR) cohort |
22 |
| Maresin 1 improves the Treg/Th17 imbalance in rheumatoid arthritis through miR-21 |
22 |
| Complement activation predicts adverse pregnancy outcome in patients with systemic lupus erythematosus and/or antiphospholipid antibodies |
22 |
| Single-cell analysis reveals fibroblast heterogeneity and myofibroblasts in systemic sclerosis-associated interstitial lung disease |
21 |
| Combined genetic and transcriptome analysis of patients with SLE: distinct, targetable signatures for susceptibility and severity |
21 |
| A20 haploinsufficiency (HA20): clinical phenotypes and disease course of patients with a newly recognised NF-kB-mediated autoinflammatory disease |
21 |
| Effects of the anti-RANKL antibody denosumab on joint structural damage in patients with rheumatoid arthritis treated with conventional synthetic disease-modifying antirheumatic drugs (DESIRABLE study): a randomised, double-blind, placebo-controlled phase 3 trial |
21 |
| Changing patterns in clinical-histological presentation and renal outcome over the last five decades in a cohort of 499 patients with lupus nephritis |
21 |
| Comparing patient-perceived and physician-perceived remission and low disease activity in psoriatic arthritis: an analysis of 410 patients from 14 countries |
20 |
| Dose reduction of baricitinib in patients with rheumatoid arthritis achieving sustained disease control: results of a prospective study |
20 |
| Evaluation of the impact of concomitant fibromyalgia on TNF alpha blockers' effectiveness in axial spondyloarthritis: results of a prospective, multicentre study |
20 |
| Evidence that tissue resident human enthesis gamma delta T-cells can produce IL-17A independently of IL-23R transcript expression |
19 |
| Similar efficacy, safety and immunogenicity of adalimumab biosimilar BI 695501 and Humira reference product in patients with moderately to severely active rheumatoid arthritis: results from the phase III randomised VOLTAIRE-RA equivalence study |
19 |
| Comparison of magnetic resonance angiography and F-18-fluorodeoxyglucose positron emission tomography in large-vessel vasculitis |
19 |
| Prediction of progression of interstitial lung disease in patients with systemic sclerosis: the SPAR model |
19 |
| The world-wide burden of musculoskeletal diseases: a systematic analysis of the World Health Organization Burden of Diseases Database |
19 |
| Lupus low disease activity state is associated with a decrease in damage progression in Caucasian patients with SLE, but overlaps with remission |
19 |
| Genome-wide meta-analysis reveals shared new loci in systemic seropositive rheumatic diseases |
19 |
| The role of IL-17A in axial spondyloarthritis and psoriatic arthritis: recent advances and controversies |
18 |
| Overdiagnosis and overtreatment in rheumatology: a little caution is in order |
18 |
| Development and initial validation of the MS score for diagnosis of macrophage activation syndrome in systemic juvenile idiopathic arthritis |
18 |
| Low-dose CT detects more progression of bone formation in comparison to conventional radiography in patients with ankylosing spondylitis: results from the SIAS cohort |
18 |
| Consensus proposal for taxonomy and definition of the autoinflammatory diseases (AIDs): a Delphi study |
18 |
| Anti-Ku syndrome with elevated CK and anti-Ku syndrome with anti-dsDNA are two distinct entities with different outcomes |
17 |
| Phase IIa, placebo-controlled, randomised study of lutikizumab, an anti-interleukin-1 alpha and anti-interleukin-1 beta dual variable domain immunoglobulin, in patients with erosive hand osteoarthritis |
17 |
| In vivo pathogenicity of IgG from patients with anti-SRP or anti-HMGCR autoantibodies in immune-mediated necrotising myopathy |
17 |
| Consensus-based recommendations for the management of juvenile localised scleroderma |
17 |
| Genetic variations in A20 DUB domain provide a genetic link to citrullination and neutrophil extracellular traps in systemic lupus erythematosus |
16 |
| Medications associated with fracture risk in patients with rheumatoid arthritis |
16 |
| Blockade of CD40-CD154 pathway interactions suppresses ectopic lymphoid structures and inhibits pathology in the NOD/ShiLtJ mouse model of Sjogren's syndrome |
16 |
| Porphyromonas gingivalis experimentally induces periodontis and an anti-CCP2-associated arthritis in the rat |
16 |
| Anti-Ro52 autoantibodies are associated with interstitial lung disease and more severe disease in patients with juvenile myositis |
16 |
| Biologic refractory disease in rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis |
16 |
| Relationship between serum urate concentration and clinically evident incident gout: an individual participant data analysis |
16 |
| Management of antiphospholipid syndrome |
16 |
| Emergent high fatality lung disease in systemic juvenile arthritis |
16 |
| Effect of rituximab on a salivary gland ultrasound score in primary Sjogren's syndrome: results of the TRACTISS randomised double- blind multicentre substudy |
16 |
| Deep Koebner phenomenon of the flexor tendon-associated accessory pulleys as a novel factor in tenosynovitis and dactylitis in psoriatic arthritis |
16 |
| Exploration of CRISPR/Cas9-based gene editing as therapy for osteoarthritis |
15 |
| Uric acid and incident dementia over 12 years of follow-up: a population-based cohort study |
15 |
| Successful reduction of overexposure in patients with rheumatoid arthritis with high serum adalimumab concentrations: an open-label, non-inferiority, randomised clinical trial |
15 |
| Two weeks versus four weeks of antibiotic therapy after surgical drainage for native joint bacterial arthritis: a prospective, randomised, non-inferiority trial |
15 |
| Early and sustained efficacy with apremilast monotherapy in biological-naive patients with psoriatic arthritis: a phase IIIB, randomised controlled trial (ACTIVE) |
15 |
| The value of F-18-FDG-PET/CT in identifying the cause of fever of unknown origin (FUO) and inflammation of unknown origin (IUO): data from a prospective study |
15 |
| Abatacept in the treatment of adult dermatomyositis and polymyositis: a randomised, phase IIb treatment delayed-start trial |
15 |
| RNA sequencing data integration reveals an miRNA interactome of osteoarthritis cartilage |
15 |
| All-cause, cause-specific and age-specific standardised mortality ratios of patients with systemic lupus erythematosus in Ontario, Canada over 43 years (1971-2013) |
15 |
| Identification of calcium pyrophosphate deposition disease (CPPD) by ultrasound: reliability of the OMERACT definitions in an extended set of joints-an international multiobserver study by the OMERACT Calcium Pyrophosphate Deposition Disease Ultrasound Subtask Force |
14 |
| Genome-wide association study revealed novel loci which aggravate asymptomatic hyperuricaemia into gout |
14 |
| Tocilizumab discontinuation after attaining remission in patients with rheumatoid arthritis who were treated with tocilizumab alone or in combination with methotrexate: results from a prospective randomised controlled study (the second year of the SURPRISE study) |
14 |
| Identification of myeloid cells in the human enthesis as the main source of local IL-23 production |
14 |
| Low-density granulocytes activate T cells and demonstrate a non-suppressive role in systemic lupus erythematosus |
14 |
| Risk of myocardial infarction with use of selected non-steroidal anti-inflammatory drugs in patients with spondyloarthritis and osteoarthritis |
14 |
| Multicriteria decision analysis process to develop new classification criteria for systemic lupus erythematosus |
14 |
| mTOR inhibition by metformin impacts monosodium urate crystal-induced inflammation and cell death in gout: a prelude to a new add-on therapy? |
14 |
| Predictors of revision, prosthetic joint infection and mortality following total hip or total knee arthroplasty in patients with rheumatoid arthritis: a nationwide cohort study using Danish healthcare registers |
14 |
| Impact of biological therapy on work outcomes in patients with axial spondyloarthritis: results from the British Society for Rheumatology Biologics Register (BSRBR-AS) and meta-analysis |
14 |
| Validation of the Psoriatic Arthritis Impact of Disease (PsAID) Questionnaire and its potential as a single-item outcome measure in clinical practice |
14 |
| 2017 EULAR recommendations for a core data set to support observational research and clinical care in rheumatoid arthritis |
14 |
| Common mental disorders within chronic inflammatory disorders: a primary care database prospective investigation |
13 |
| Influence of disease activity and medications on offspring birth weight, pre-eclampsia and preterm birth in systemic lupus erythematosus: a population-based study |
13 |
| Stepwise dose increase of febuxostat is comparable with colchicine prophylaxis for the prevention of gout flares during the initial phase of urate-lowering therapy: results from FORTUNE- a prospective, multicentre randomised study |
13 |
| Etanercept in patients with inflammatory hand osteoarthritis (EHOA): a multicentre, randomised, double-blind, placebo-controlled trial |
13 |
| Gout, Hyperuricaemia and Crystal-Associated Disease Network (G-CAN) consensus statement regarding labels and definitions of disease states of gout |
13 |
| Phase III trial results with blisibimod, a selective inhibitor of B-cell activating factor, in subjects with systemic lupus erythematosus (SLE): results from a randomised, double-blind, placebo-controlled trial |
13 |
| Protein kinases G are essential downstream mediators of the antifibrotic effects of sGC stimulators |
13 |
| Critical role of neutrophil extracellular traps (NETs) in patients with Behcet's disease |
13 |
| Comparative effectiveness of tocilizumab versus TNF inhibitors as monotherapy or in combination with conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis after the use of at least one biologic disease-modifying antirheumatic drug: analyses from the pan- European TOCERRA register collaboration |
13 |
| Measurement properties of the ASAS Health Index: results of a global study in patients with axial and peripheral spondyloarthritis |
13 |
| ADJUVITE: a double-blind, randomised, placebo-controlled trial of adalimumab in early onset, chronic, juvenile idiopathic arthritis-associated anterior uveitis |
13 |
| Treat to target (drug-free) inactive disease in DMARD-naive juvenile idiopathic arthritis: 24-month clinical outcomes of a three-armed randomised trial |
13 |
| microRNA-181a-5p antisense oligonucleotides attenuate osteoarthritis in facet and knee joints |
13 |
| Effectiveness of low-dose radiation therapy on symptoms in patients with knee osteoarthritis: a randomised, double-blinded, sham-controlled trial |
13 |
| Derivation and validation of the SLE Disease Activity Score (SLE-DAS): a new SLE continuous measure with high sensitivity for changes in disease activity |
13 |
| Risk of serious infections in patients with rheumatoid arthritis treated in routine care with abatacept, rituximab and tocilizumab in Denmark and Sweden |
12 |
| Validation of the ANCA-associated vasculitis patient-reported outcomes (AAV-PRO) questionnaire |
12 |
| Gradual tapering TNF inhibitors versus conventional synthetic DMARDs after achieving controlled disease in patients with rheumatoid arthritis: first-year results of the randomised controlled TARA study |
12 |
| Drug-induced systemic lupus: revisiting the ever-changing spectrum of the disease using the WHO pharmacovigilance database |
12 |
| Connective tissue growth factor contributes to joint homeostasis and osteoarthritis severity by controlling the matrix sequestration and activation o latent TGF beta |
12 |
| Baseline ultrasound examination as possible predictor of relapse in patients affected by juvenile idiopathic arthritis (JIA) |
12 |
| Lupus Low Disease Activity State (LLDAS) discriminates responders in the BLISS-52 and BLISS-76 phase III trials of belimumab in systemic lupus erythematosus |
12 |
| Active immunisation targeting nerve growth factor attenuates chronic pain behaviour in murine osteoarthritis |
12 |
| First Latin American clinical practice guidelines for the treatment of systemic lupus erythematosus: Latin American Group for the Study of Lupus (GLADEL, Grupo Latino Americano de Estudio del Lupus)-Pan-American League of Associations of Rheumatology (PANLAR) |
12 |
| Hexokinase 2 as a novel selective metabolic target for rheumatoid arthritis |
12 |
| Synovial tissue signatures enhance clinical classification and prognostic/treatment response algorithms in early inflammatory arthritis and predict requirement for subsequent biological therapy: results from the pathobiology of early arthritis cohort (PEAC) |
12 |
| Do patients with axial spondyloarthritis with radiographic sacroiliitis fulfil both the modified New York criteria and the ASAS axial spondyloarthritis criteria? Results from eight cohorts |
12 |
| Characteristics of difficult-to-treat rheumatoid arthritis: results of an international survey |
12 |
| Impact of temporary methotrexate discontinuation for 2 weeks on immunogenicity of seasonal influenza vaccination in patients with rheumatoid arthritis: a randomised clinical trial |
12 |
| Intrarenal activation of adaptive immune effectors is associated with tubular damage and impaired renal function in lupus nephritis |
12 |
| Galectin-9 is an easy to measure biomarker for the interferon signature in systemic lupus erythematosus and antiphospholipid syndrome |
12 |
| Differential ubiquitination in NETs regulates macrophage responses in systemic lupus erythematosus |
12 |
| Risk of losing remission, low disease activity or radiographic progression in case of bDMARD discontinuation or tapering in rheumatoid arthritis: systematic analysis of the literature and meta-analysis |
12 |
| Patterns and predictors of skin score change in early diffuse systemic sclerosis from the European Scleroderma Observational Study |
12 |
| Cigarette smoking and the risk of systemic lupus erythematosus, overall and by anti-double stranded DNA antibody subtype, in the Nurses' Health Study cohorts |
11 |
| Ideal target for psoriatic arthritis? Comparison of remission and low disease activity states in a real-life cohort |
11 |
| High-sensitive troponin is associated with subclinical imaging biosignature of inflammatory cardiovascular involvement in systemic lupus erythematosus |
11 |
| Canakinumab in patients with systemic juvenile idiopathic arthritis and active systemic features: results from the 5-year long-term extension of the phase III pivotal trials |
11 |
| Development of the CT Syndesmophyte Score (CTSS) in patients with ankylosing spondylitis: data from the SIAS cohort |
11 |
| Mast cells in early rheumatoid arthritis associate with disease severity and support B cell autoantibody production |
11 |
| Increased autophagy is cytoprotective against podocyte injury induced by antibody and interferon-alpha in lupus nephritis |
11 |
| Stratification of knee osteoarthritis: two major patient subgroups identified by genome-wide expression analysis of articular cartilage |
11 |
| Aberrant tRNA processing causes an autoinflammatory syndrome responsive to TNF inhibitors |
11 |
| Clinical characteristics and genetic analyses of 187 patients with undefined autoinflammatory diseases |
11 |
| Effects of BI 65 an antagonistic anti-CD40 antibody, on clinical and biomarker variables in patients with active rheumatoid arthritis: a randomised, double-blind, placebo-controlled, phase IIa study |
11 |
| Incidence of hip and knee replacement in patients with rheumatoid arthritis following the introduction of biological DMARDs: an interrupted time-series analysis using nationwide Danish healthcare registers |
11 |
| Normal mortality of the COBRA early rheumatoid arthritis trial cohort after 23 years of follow-up |
11 |
| Defining refractory rheumatoid arthritis |
11 |
| Hypermetabolic macrophages in rheumatoid arthritis and coronary artery disease due to glycogen synthase kinase 3b inactivation |
11 |
| The STAT4 SLE risk allele rs7574865[T] is associated with increased IL-12-induced IFN-gamma production in T cells from patients with SLE |
11 |
| Non-classical monocytes as mediators of tissue destruction in arthritis |
11 |
| Rheumatoid arthritis-associated DNA methylation sites in peripheral blood mononuclear cells |
11 |
| An Assessment in SpondyloArthritis International Society (ASAS)-endorsed definition of clinically important worsening in axial spondyloarthritis based on ASDAS |
11 |
| Association of synovial tissue polyfunctional T-cells with DAPSA in psoriatic arthritis |
11 |
| HLA class I and II alleles in susceptibility to ankylosing spondylitis |
10 |
| Smoking paradox in the development of psoriatic arthritis among patients with psoriasis: a population-based study |
10 |
| Clinical and radiological outcomes of 5-year drug-free remission-steered treatment in patients with early arthritis: IMPROVED study |
10 |
| Deregulation of microRNA expression in purified T and B lymphocytes from patients with primary Sjogren's syndrome |
10 |
| Molecular profile and proangiogenic activity of the adipose-derived stromal vascular fraction used as an autologous innovative medicinal product in patients with systemic sclerosis |
10 |
| Consensus-based recommendations for the management of uveitis associated with juvenile idiopathic arthritis: the SHARE initiative |
10 |
| Tolerising cellular therapies: what is their promise for autoimmune disease? |
10 |
| Lupus Low Disease Activity State (LLDAS) attainment discriminates responders in a systemic lupus erythematosus trial: post-hoc analysis of the Phase IIb MUSE trial of anifrolumab |
10 |
| Circulating follicular helper T cells are increased in systemic sclerosis and promote plasmablast differentiation through the IL-21 pathway which can be inhibited by ruxolitinib |
10 |
| Different classes of anti-modified protein antibodies are induced on exposure to antigens expressing only one type of modification |
10 |
| Focused HLA analysis in Caucasians with myositis identifies significant associations with autoantibody subgroups |
10 |
| Cardiovascular, thromboembolic and renal outcomes in IgA vasculitis (Henoch-Schonlein purpura): a retrospective cohort study using routinely collected primary care data |
10 |
| ACPA IgG galactosylation associates with disease activity in pregnant patients with rheumatoid arthritis |
10 |
| Shared epitope defines distinct associations of cigarette smoking with levels of anticitrullinated protein antibody and rheumatoid factor |
10 |
| Presence of monosodium urate crystal deposition by dual-energy CT in patients with gout treated with allopurinol |
10 |
| Cleaved N-terminal histone tails distinguish between NADPH oxidase (NOX)-dependent and NOX-independent pathways of neutrophil extracellular trap formation |
10 |
| Risk of second malignant neoplasm and mortality in patients with rheumatoid arthritis treated with biological DMARDs: a Danish population-based cohort study |
10 |
